Drug Profile


Alternative Names: Anti-CD3 X anti-HER-2/neu; Rexomab®; Rexomun

Latest Information Update: 08 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TRION Pharma
  • Developer Fresenius Biotech; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 14 Aug 2009 Discontinued - Phase-II for Breast cancer in Europe (IV)
  • 03 Jun 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top